Lowery’s appointment goes into effect on March 2, 2026. At that time, he will also join the board of directors for the provider of healthcare solutions to dental and medical professionals.
The Melville, New York–based company’s soon-to-be new CEO succeeds Stanley M. Bergman, who stepped down from the post. Bergman spent more than 35 years as CEO before announcing his intent to retire in July 2025. Henry Schein said at the end of last year that it expected to name its CEO in mid-January.
Bergman will continue to serve as chair of the board to ensure a smooth and effective transition.
Lowery joins Henry Schein with more than two decades of healthcare experience. His track record includes scaling complex businesses and driving growth and value creation. Most recently, he served as EVP and president, Laboratory Products and BioProduction at Thermo Fisher Scientific. There, he led Thermo Fisher’s distribution channel’s above-market performance. Before Thermo Fisher, Lowery held leadership roles at companies including Maytag and General Motors.
Henry Schein said Lowery’s experience in growing distribution and owned product businesses, including manufacturing, R&D, marketing and sales, closely aligns with its business model. The company expects Lowery to guide it through its next phase of growth.
Commentary from Henry Schein officials
Lowery, the company’s soon-to-be CEO, said:
“I am honored to join Henry Schein at such a pivotal moment. This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service, and partnership. I look forward to working with Team Schein to build on the strong foundation established by Stan while accelerating value creation.”
Bergman said:
“I am very pleased to welcome Fred to Henry Schein. Beyond his extensive operational experience, he brings a leadership philosophy that reflects the values that have long defined our company. Fred understands the critical role we play in supporting dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth.”
Phil Laskawy, lead director and chair of Henry Schein’s Nominating and Governance Committee, said:
“On behalf of the board, I would like to thank Stan for his exceptional leadership and invaluable contributions over more than three decades. After a comprehensive search process, we are confident that Fred is the right successor to honor Henry Schein’s proud heritage. With extensive commercial, logistics, and manufacturing expertise, and a focus on customer satisfaction, he has the combination of experience and capabilities necessary to accelerate growth and value creation.”
Max Lin, board member and vice chair of the Nominating and Governance Committee, said:
“We are excited about our strategic partnership with Henry Schein and look forward to supporting the next chapter of the company’s journey under Fred’s leadership. We believe Fred brings a unique combination of healthcare distribution experience, operational best practices, and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a world-class business.”
